Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
08/2012
08/23/2012WO2012091564A3 A cross linking polypeptide comprising an hexameric single chain antibody binding mhc-mage complex that induces apoptosis
08/23/2012WO2012091496A3 siRNA FOR INHIBITION OF Hif1α EXPRESSION AND ANTICANCER COMPOSITION CONTAINING THE SAME
08/23/2012WO2012089633A9 Novel pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
08/23/2012WO2012088388A9 Treating multiple myeloma
08/23/2012WO2012086964A3 Amphiphilic cyclic phosphazene trimer, hydrophobic pharmaceutical formulation micellized by amphiphilic cyclic phosphazene trimer, and preparation methods thereof
08/23/2012WO2012075075A3 Methods and systems for spatially identifying abnormal cells
08/23/2012WO2012074249A3 Novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition with inhibitory activity against raf kinase, containing same as active ingredient
08/23/2012WO2012064146A3 Anticancer composition containing gkn 1
08/23/2012WO2012061443A3 Compositions of a peptide targeting system for treating cancer
08/23/2012WO2012061015A3 L-citrulline supplementation during arginine depletion therapy with arginase
08/23/2012WO2012054792A3 Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells
08/23/2012WO2012039908A4 Method and compound for treatment of cancer using phosphorous-32 labeled dna
08/23/2012WO2011163483A3 Polymers for biomaterials and therapeutics
08/23/2012WO2011143656A3 Compositions and methods of identifying tumor specific neoantigens
08/23/2012US20120214880 Cancer screening by detection of ultrastructural and molecular markers
08/23/2012US20120214869 Novel ligand activators of the rar receptors and pharmaceutical/cosmetic applications thereof
08/23/2012US20120214864 Mirnas dysregulated in triple-negative breast cancer
08/23/2012US20120214858 Imidamide sphingosine kinase inhibitors
08/23/2012US20120214856 Treatment for cancer
08/23/2012US20120214855 Heterocyclic compound and use thereof
08/23/2012US20120214853 ITE for Cancer Intervention and Eradication
08/23/2012US20120214850 Compounds for treatment of cell proliferative diseases
08/23/2012US20120214848 [1,2,4]oxadiazol-3-yl acid salts and crystalline forms and their preparation
08/23/2012US20120214847 2-[1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS
08/23/2012US20120214846 Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators
08/23/2012US20120214842 Methods for treating diseases of the retina
08/23/2012US20120214841 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
08/23/2012US20120214840 Indolizine inhibitors of 5-lipoxygenase
08/23/2012US20120214837 Substituted 6,7-dialkoxy-3-isoquinolinol derivatives as inhibitors of phosphodiesterase 10 (pde10a)
08/23/2012US20120214836 Sensitizer, pharmaceutical composition, kit and use for target therapy
08/23/2012US20120214835 Sensitizer, kit and use for cancer therapy
08/23/2012US20120214834 Immune enhancement composition and kit and use thereof
08/23/2012US20120214832 Isoform selective phospholipase d inhibitors
08/23/2012US20120214831 Method for determination of sensitivity to anti-cancer agent
08/23/2012US20120214830 Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
08/23/2012US20120214829 Molecular Predictors of Therapeutic Response to Specific Anti-Cancer Agents
08/23/2012US20120214828 Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
08/23/2012US20120214826 Inhibitors of bruton's tyrosine kinase
08/23/2012US20120214825 mTOR/JAK INHIBITOR COMBINATION THERAPY
08/23/2012US20120214824 Proteostasis regulators
08/23/2012US20120214823 Novel compounds that are erk inhibitors
08/23/2012US20120214814 Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at c-17
08/23/2012US20120214813 Isoxazole compound for the treatment of cancer
08/23/2012US20120214811 Raf inhibitor compounds and methods of use thereof
08/23/2012US20120214810 Salts of N-[6-cis-2,6-Dimethylmorpholin-4-yl)pyridine-3-yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide
08/23/2012US20120214806 3-amino-5-phenyl-5,6-dihydro-2h-[1,4]oxazines
08/23/2012US20120214801 Compositions and methods relating to novel compounds and targets thereof
08/23/2012US20120214800 Organic Compounds
08/23/2012US20120214799 Kinase inhibitors
08/23/2012US20120214796 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
08/23/2012US20120214795 Fused heterocyclic ring derivative and use thereof
08/23/2012US20120214794 Heteroaryls and uses thereof
08/23/2012US20120214787 Oxadiazole inhibitors of leukotriene production
08/23/2012US20120214778 FULVESTRANT IN A DOSAGE OF 500mg FOR THE TREATMENT OF ADVANCED BREAST CANCER
08/23/2012US20120214775 Pharmaceutical Salts of 3-O-(3',3'-Dimethylsuccinyl) Betulinic Acid
08/23/2012US20120214774 Treatment of solid tumors with rapamycin derivatives
08/23/2012US20120214770 Substituted benzofurans, benzothiophenes, benzoselenophenes and indoles and their use as tubulin polymerisation inhibitors
08/23/2012US20120214768 Novel pyridopyrazine derivatives, process of manufacturing and uses thereof
08/23/2012US20120214767 Tricyclic heterocyclic compounds
08/23/2012US20120214762 6,5-heterocyclic propargylic alcohol compounds and uses therefor
08/23/2012US20120214758 Tyrosine kinase receptor antagonists and methods of treatment for pancreatic cancer
08/23/2012US20120214757 Methods and Compositions for Treating Cancer Using Proteasome Inhibitors
08/23/2012US20120214749 Microparticles comprising somatostatin analogues
08/23/2012US20120214744 Polypeptides and nucleic acids for treating erbb2-dependent cancers
08/23/2012US20120214741 Vdac1 compositions and methods of use thereof for regulating apoptosis
08/23/2012US20120214737 Methods for protecting dopaminergic neurons from stress and promoting proliferation and differentiation of oligodendrocyte progenitors by nrg-2
08/23/2012US20120214733 Oxytocin receptor agonists
08/23/2012US20120214732 Inhibitors of the Trypsin-Like Site of the Proteasome and Methods of Use Thereof
08/23/2012US20120214206 VECTORS FOR MOLECULE DELIVERY TO CD11b EXPRESSING CELLS
08/23/2012US20120213872 Compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof
08/23/2012US20120213867 Raf inhibitors for the treatment of thyroid cancer
08/23/2012US20120213863 Therapeutic gas for the treatment of mitochondrial disorders
08/23/2012US20120213854 Methods of treating a subject and related particles, polymers and compositions
08/23/2012US20120213844 Liposome composition for targeting egfr receptor
08/23/2012US20120213842 Methods of making and using compositions comprising flavonoids
08/23/2012US20120213839 Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
08/23/2012US20120213831 Microspheres for active embolization
08/23/2012US20120213829 Dry powder aerosols of nanoparticulate drugs
08/23/2012US20120213828 Adenovirus vaccine vector and methods of use
08/23/2012US20120213823 Compositions comprising polyunsaturated fatty acid monoglycerides, derivatives thereof and uses thereof
08/23/2012US20120213822 Chemo-immunotherapy method
08/23/2012US20120213818 Combination therapy for immunostimulation
08/23/2012US20120213815 Vaccines and immunotherapeutics using codon-optimized il-15 and methods for using the same
08/23/2012US20120213813 Alphavirus replicon particles as immunological adjuvants
08/23/2012US20120213809 Vault complexes for cytokine delivery
08/23/2012US20120213805 Amatoxin-Armed Tartget-Binding Moieties for the Treatment of Cancer
08/23/2012US20120213804 Calicheamicin derivative-carrier conjugates
08/23/2012US20120213803 Methods for diagnosing and treating encephalitis or epilepsy
08/23/2012US20120213801 Phosphorylated Twist1 and cancer
08/23/2012US20120213798 Methods and uses for treating hepatic ischemia and reperfusion injury
08/23/2012US20120213793 Cancer treatment
08/23/2012US20120213791 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulators
08/23/2012US20120213789 New Molecular Target for Treatment of Cancer
08/23/2012US20120213788 Use of inhibitors of leukotriene b4 receptor blt2 for treating human cancers
08/23/2012US20120213786 Notch1 Binding Agents and Methods of Use Thereof
08/23/2012US20120213783 Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
08/23/2012US20120213778 Method of detecting and treating tuberous sclerosis complex associated disorders
08/23/2012US20120213777 Vascular endothelial growth factor 2
08/23/2012US20120213773 Binding domain-immunoglobulin fusion proteins
08/23/2012US20120213771 Antibodies that bind human cd27 and uses thereof
1 ... 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 ... 2211